AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27758726 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26289234 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned DDI alerts
Number of subjects: 20
Study 26289234 — intervention group
Group type: COMPARATOR
Intervention: Original DDI alerts
Number of subjects: 20
Study 23593478 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal Stimulation (50-second cold pressor stimulation, immersing the foot in 0-2° C water)
Number of subjects: 68
Study 23593478 — intervention group
Group type: COMPARATOR
Intervention: Sham Control (immersing the foot in room temperature water)
Number of subjects: 68
Study 21880911 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF(1) antagonist GW876008
Number of subjects: 0
Study 21880911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18568411 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-knot running technique with Lapra-Ty clips
Number of subjects: 50
Study 18568411 — intervention group
Group type: COMPARATOR
Intervention: Single-knot running technique without Lapra-Ty clips
Number of subjects: 50
Study 17299480 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index preload (Ovaltine Light)
Number of subjects: 12
Study 17299480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index preload (milk)
Number of subjects: 12
Study 17299480 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive control (water)
Number of subjects: 12
Study 17299480 — intervention group
Group type: EXPERIMENTAL
Intervention: All preloads
Number of subjects: 12
Study 15615349 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 15615349 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of drugs with complementary mechanisms
Number of subjects: 0
Study 11977649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative intra-arterial infusion chemotherapy (mitomycin 10 mg, 5-FU 1,000 mg, epirubicin 60 mg)
Number of subjects: 28
Study 11977649 — intervention group
Group type: COMPARATOR
Intervention: Control (no pre-operative intra-arterial infusion chemotherapy)
Number of subjects: 28
Study 9737101 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS fentanyl (25, 50, 75, or 100 micrograms/hr) administered as a transdermal patch every 3 days
Number of subjects: 53
Study 9737101 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS fentanyl
Number of subjects: 53
Study 8287749 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine (0.5 g three times/day)
Number of subjects: 38
Study 8287749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enemas (4 g of 5-aminosalicylic acid enema every third night)
Number of subjects: 38
Study 8287749 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalazine
Number of subjects: 38
Study 8287749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enemas
Number of subjects: 38
Study 2576397 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.05 mg daily)
Number of subjects: 10
Study 2576397 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (mean 0.09 mg a day)
Number of subjects: 10
Study 2576397 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502
Number of subjects: 10
Study 795022 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg a day of zinc metal supplement with 0.50 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg a day of zinc metal supplement with 1 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.50 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 1 g a day of penicillamine
Number of subjects: 66
Study 795022 — intervention group
Group type: COMPARATOR
Intervention: Placebo with zinc supplement
Number of subjects: 66
Study 31977236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagan spell-casting intervention (Group A: weeks 1-2; Group B: weeks 2-3)
Number of subjects: 44
Study 31977236 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B: delayed intervention)
Number of subjects: 44
Study 31000844 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 45
Study 31000844 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullaby
Number of subjects: 45
Study 31000844 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 27592680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (200 mg)
Number of subjects: 100
Study 27592680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (200 mg)
Number of subjects: 100
Study 27592680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin (800 mg)
Number of subjects: 100
Study 27592680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination lactoferrin/immunoglobulin (200 mg/200 mg)
Number of subjects: 100
Study 27592680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination lactoferrin/immunoglobulin (200 mg/800 mg)
Number of subjects: 100
Study 27592680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25760977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles with a fixed 3-month interval after the first four courses)
Number of subjects: 148
Study 25760977 — intervention group
Group type: COMPARATOR
Intervention: Continuous docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles)
Number of subjects: 148
Study 22268979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based treatment (MBT, n = 12)
Number of subjects: 20
Study 22268979 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral treatment (CBT, n = 8)
Number of subjects: 20
Study 20628646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing the letter name prior to the detection task
Number of subjects: 0
Study 20628646 — intervention group
Group type: COMPARATOR
Intervention: Visual cue in the form of a preview of the to-be-detected letter
Number of subjects: 0
Study 18779611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 489
Study 18779611 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m(2))
Number of subjects: 489
Study 16395996 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds Ratio (OR)
Number of subjects: 0
Study 16395996 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Risk (RR)
Number of subjects: 0
Study 16395996 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference (DEL)
Number of subjects: 0
Study 16395996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact Fisher type test for one-sided equivalence
Number of subjects: 0
Study 16395996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian test for non-inferiority
Number of subjects: 0
Study 12507207 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study 12507207 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques
Number of subjects: 0
Study 10494379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1.0 g administered intravenously 15 minutes prior to surgery
Number of subjects: 31
Study 10494379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 31
Study 8942008 — intervention group
Group type: EXPERIMENTAL
Intervention: D'Allergen treatment
Number of subjects: 30
Study 8942008 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated homes)
Number of subjects: 30
Study 1683593 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitisation (ID)
Number of subjects: 120
Study 1683593 — intervention group
Group type: COMPARATOR
Intervention: Other behavioural procedures (control)
Number of subjects: 120
Study 6125483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofizopam (100 mg)
Number of subjects: 47
Study 6125483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofizopam (100 mg, three times)
Number of subjects: 47
Study 6125483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30808899 — intervention group
Group type: EXPERIMENTAL
Intervention: real-NMMS (rNMMS)
Number of subjects: 22
Study 30808899 — intervention group
Group type: COMPARATOR
Intervention: sham NMMS (sNMMS)
Number of subjects: 22
Study 29268764 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS and sham PES (group 1; n = 20)
Number of subjects: 80
Study 29268764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham tDCS and active PES (group 2; n = 20)
Number of subjects: 80
Study 29268764 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and PES (group 3; n = 20)
Number of subjects: 80
Study 29268764 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and PES (group 4; n = 20)
Number of subjects: 80
Study 29268764 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 80
Study 25715664 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose X-ray examination (0.365 mSv)
Number of subjects: 289
Study 25715664 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose X-ray examination (0.211 mSv)
Number of subjects: 289
Study 24515928 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program with telerehabilitation monitoring; practice at least twice a week at the kiosk and at least 3 more days a week at home.
Number of subjects: 0
Study 24515928 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23027657 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18
Study 23027657 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg lorazepam
Number of subjects: 18
Study 23027657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19653743 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal masking
Number of subjects: 0
Study 19653743 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous masking
Number of subjects: 0
Study 17723159 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicinal product containing Tropaeoli majoris herba and Armoraciae rusticanae radix, administered twice daily for 90 days.
Number of subjects: 174
Study 17723159 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice daily for 90 days.
Number of subjects: 174
Study 16469334 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoints Program (intervention families received persuasive communications and a parent-teen driving agreement)
Number of subjects: 3743
Study 16469334 — intervention group
Group type: COMPARATOR
Intervention: Standard information on driver safety (comparison families)
Number of subjects: 3743
Study 12720074 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride plus IL-2
Number of subjects: 301
Study 12720074 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 301
Study 10921531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 0
Study 10921531 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 8781825 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg t.i.d.) as adjuvant therapy to standard therapy
Number of subjects: 77
Study 8781825 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (thrombolysis, beta-blockers, and nitrates)
Number of subjects: 77
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 41
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25.0 mg
Number of subjects: 41
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril low dose group (incremental doses of 6.25, 12.5, and 25.0 mg)
Number of subjects: 41
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril high dose group (25.0 mg 8 hourly)
Number of subjects: 41
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (both doses)
Number of subjects: 41
Study 1464341 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 41
Study 6099135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2-adrenoceptor agonist alpha-methylnoradrenaline (MNA)
Number of subjects: 0
Study 6099135 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (A II)
Number of subjects: 0
Study 30528770 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (MOIT)
Number of subjects: 55
Study 30528770 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-binding epitopes
Number of subjects: 55
Study 30528770 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum model using 6 IgE-binding epitopes
Number of subjects: 55
Study 28429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow or goat milk-based infant formulae (combined groups)
Number of subjects: 180
Study 25567231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² for in vivo purging 3-5 days pre-stem cell collection and 2×4 weekly at 2 and 6 months post-ASCT)
Number of subjects: 73
Study 25567231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (three infusions pre-stem cell collection followed by 6× R weekly and interferon-α 3 MU/m² SC TIW)
Number of subjects: 73
Study 25567231 — intervention group
Group type: COMPARATOR
Intervention: High-dose therapy and autologous stem cell transplantation (HDT/ASCT) without rituximab
Number of subjects: 73
Study 25362822 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of omega-3
Number of subjects: 60
Study 25362822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of omega-3
Number of subjects: 60
Study 25362822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin E 200 IU)
Number of subjects: 60
Study 20434293 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based supportive intervention for parents of young children with T1D
Number of subjects: 24
Study 19745745 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1263
Study 19745745 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 1263
Study 17404792 — intervention group
Group type: EXPERIMENTAL
Intervention: E-PEG
Number of subjects: 30
Study 17404792 — intervention group
Group type: COMPARATOR
Intervention: Pull-method PEG
Number of subjects: 30
Study 14960741 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide group
Number of subjects: 452
Study 14960741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 452
Study 11307124 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 66
Study 11307124 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study 9399309 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided cognitive rehabilitation (six 1-hr sessions)
Number of subjects: 10
Study 9399309 — intervention group
Group type: COMPARATOR
Intervention: Graphics-based computer games (six sessions)
Number of subjects: 10
Study 7962339 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (dose required to increase resting heart rate by 25 beats/min)
Number of subjects: 8
Study 7962339 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75 g) administration
Number of subjects: 8
Study 7962339 — intervention group
Group type: COMPARATOR
Intervention: Glucose administration
Number of subjects: 8
Study 7962339 — intervention group
Group type: COMPARATOR
Intervention: Symptoms after glucose intake
Number of subjects: 8
Study 7962339 — intervention group
Group type: COMPARATOR
Intervention: SCL-90R questionnaire
Number of subjects: 8
Study 2894081 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily for three days
Number of subjects: 14
Study 2894081 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg three hours before challenge
Number of subjects: 14
Study 2894081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2894081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flurbiprofen and terfenadine
Number of subjects: 14
Study 31866308 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg 3 x daily for 10 days)
Number of subjects: 20
Study 31866308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x daily for 10 days)
Number of subjects: 20
Study 31866308 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal (150 mg caffeine 3 x daily for eight days, followed by placebo for two days)
Number of subjects: 20
Study 30484824 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval appendectomy
Number of subjects: 60
Study 30484824 — intervention group
Group type: COMPARATOR
Intervention: Follow-up with magnetic resonance imaging
Number of subjects: 60
Study 30484824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29231430 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) for 30 min before and after embryo transfer, applied on specific acupoints.
Number of subjects: 1761
Study 29231430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TEAS).
Number of subjects: 1761
Study 26112723 — intervention group
Group type: EXPERIMENTAL
Intervention: POTTS-E group
Number of subjects: 65
Study 26112723 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 23772581 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and rehabilitation treatment (Group 1)
Number of subjects: 390
Study 23772581 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (Group 2)
Number of subjects: 390
Study 22115059 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Preventive Health Record (IPHR)
Number of subjects: 14
Study 22115059 — intervention group
Group type: EXPERIMENTAL
Intervention: IPHR
Number of subjects: 14
Study 19502748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid (DGLA)-enriched oil (50 or 150 mg as free DGLA)
Number of subjects: 0
Study 19502748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid (DGLA)-enriched oil
Number of subjects: 0
Study 17035557 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT
Number of subjects: 121
Study 17035557 — intervention group
Group type: COMPARATOR
Intervention: Clubhouse
Number of subjects: 121
Study 15525889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemo Embolization (TACE)
Number of subjects: 89
Study 15525889 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Ethanol Injection (PEI)
Number of subjects: 89
Study 15525889 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Thermal Ablation (LTA)
Number of subjects: 89
Study 15525889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 89
Study 12727079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone with dexamethasone (group 1)
Number of subjects: 12
Study 12727079 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone alone (group 2)
Number of subjects: 12
Study 10962414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1040
Study 10962414 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 1040
Study 8796773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous bolus of ephedrine (10 mg)
Number of subjects: 122
Study 8796773 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic ephedrine)
Number of subjects: 122
Study 8796773 — intervention group
Group type: EXPERIMENTAL
Intervention: Among newborns of hypotensive mothers (ephedrine group)
Number of subjects: 122
Study 8796773 — intervention group
Group type: COMPARATOR
Intervention: Among newborns of hypotensive mothers (control group)
Number of subjects: 122
Study 1519607 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 32
Study 1519607 — intervention group
Group type: COMPARATOR
Intervention: Control (drug therapy)
Number of subjects: 32
Study 6322710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily)
Number of subjects: 36
Study 6322710 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (500,000 units four times daily)
Number of subjects: 36
Study 6322710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 36
Study 6322710 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 36
Study 30776384 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 0
Study 30776384 — intervention group
Group type: COMPARATOR
Intervention: Ultrathin Descemet stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 0
Study 30523434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor genetic profiling (NGS implementation)
Number of subjects: 0
Study 30523434 — intervention group
Group type: COMPARATOR
Intervention: Not receiving tumor genetic profiling (control group)
Number of subjects: 0
Study 27098427 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 18
Study 27098427 — intervention group
Group type: COMPARATOR
Intervention: Axitinib plus lomustine
Number of subjects: 18
Study 24361207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program (PEP); 8-week training program, once a week, including warm-up exercises, muscle strengthening, stretching, balancing, and self-administered massage to acupressure points.
Number of subjects: 396
Study 24361207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEP);
Number of subjects: 396
Study 24361207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise Program (PEP);
Number of subjects: 396
Study 22149546 — intervention group
Group type: COMPARATOR
Intervention: hsCRP in subjects with NAFLD (4.2±1.2 mg/L)
Number of subjects: 200
Study 22149546 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte count in subjects with NAFLD (7.8±1.4×10(3)/μL)
Number of subjects: 200